低剂量口服大麻素治疗可以减少小鼠动脉样硬化的进展
Sabine Steffens1, Niels R Veillard, Claire Arnaud
1Division of Cardiology, Department of Medicine, Foundation for Medical Research, University Hospital, Faculty of Medicine, 1211 Geneva, Switzerland.
Nature
|April 9, 2005
概括
低剂量的delta-9-tetrahydrocannabinol (THC) 有效地抑制了小鼠的动脉样硬化进展. 这种治疗针对免疫细胞上的CB2受体,为治疗心血管疾病提供了潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 心血管科学 心血管科学
背景情况:
- 动脉样硬化是一种慢性炎症性疾病,是心脏病和中风的主要原因.
- 类大麻素衍生物,比如delta-9-tetrahydrocannabinol (THC),调节免疫功能,并显示出治疗炎症疾病的潜力.
研究的目的:
- 在小鼠模型中研究THC对已确定的动脉样硬化的影响.
- 为了确定低剂量的THC,低于精神药物水平,是否会影响动脉样硬化进展.
- 探索CB2受体在THC抗动脉样硬化作用中的作用.
主要方法:
- 向已确定的动脉样硬化症的阿波利波蛋白E淘汰赛小鼠口服THC (每天1毫克~1千克)
- 分析了疾病进展,免疫细胞功能 (淋巴细胞增殖,干扰素-分泌) 和巨细胞化学反应.
- 使用一种特定的CB2受体对手来阻止THC的作用.
- 在人类和小鼠动脉样硬化斑块中检测到CB2受体表达.
主要成果:
- 口服THC显著抑制动脉样硬化进展在低,非精神药物剂量.
- THC降低了淋巴细胞的增殖和干扰素-玛分泌.
- 在体外,THC抑制了巨细胞的化学反应.
- 所有观察到的效应都被CB2受体对抗剂阻断,证实了它的作用.
结论:
- 低剂量口服THC治疗有效地抑制了小鼠模型中的动脉样硬化进展.
- THC通过CB2受体对淋巴细胞和骨髓细胞产生类免疫调节作用.
- 针对CB2受体的THC和CB2受体向性大麻素代表了动脉样硬化治疗的潜在治疗策略.
相关概念视频
01:21Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...